New hope for acromegaly patients: drug may prevent spine fractures
NCT ID NCT07179926
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This study looks at two medications for acromegaly, a condition where the body makes too much growth hormone. The goal is to see which drug better prevents spine fractures, a common and painful problem. About 120 adults whose acromegaly is not well-controlled will take either Pasireotide LAR or Pegvisomant and be monitored for one year. The results could help doctors choose the best treatment to protect bones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Endocrinologia e Diabetologia
RECRUITINGRome, RM, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.